Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 18, Number 12—December 2012

No Evidence of Prolonged Hendra Virus Shedding by 2 Patients, Australia

Article Metrics
citations of this article
EID Journal Metrics on Scopus
Carmel Taylor, Elliott G. Playford, William J.H. McBride, Jamie McMahon, and David WarrilowComments to Author 
Author affiliations: Queensland Health Forensic and Scientific Services, Archerfield, Queensland, Australia (C. Taylor, J. McMahon, D. Warrilow); Princess Alexandra Hospital, Brisbane, Queensland, Australia (E.G. Playford); University of Queensland School of Medicine, Brisbane (E.G. Playford); and James Cook University School of Medicine and Dentistry, Cairns, Queensland, Australia (W.J.H. McBride)

Cite This Article


To better understand the natural history of Hendra virus infection and its tendency to relapse, 2 humans infected with this virus were monitored after acute infection. Virus was not detected in blood samples when patients were followed-up at 2 and 6 years. Thus, no evidence was found for prolonged virus shedding.

Most virus infections resolve after an acute phase. A small subset can cause persistent infection and result in continual shedding of virus, and others use a latency mechanism to evade the host immune response. Hendra and Nipah viruses (family Paramyxoviridae, genus Henipavirus) can cause respiratory disease and encephalitis in humans. Hendra virus infection is acquired by close contact with horses infected by spillover infection from fruit bats, which are the natural reservoir for these viruses (1).

In a small proportion of cases, relapse with encephalitis after a mild acute phase is a feature of henipavirus infection and is often fatal. For example, several cases of relapsing encephalitis caused by Nipah infection in humans have been reported (24), as well as 1 case caused by Hendra virus in a human (5,6). Whether virus shedding occurs after an acute infection of any severity is currently unclear. Because standard veterinary practice in Australia is to destroy animals that survive natural or experimental Hendra virus infection (7), long-term monitoring for virus shedding has not been possible.

To address the nature of viral persistence in cases of Hendra virus infection, virus shedding and serologic changes were monitored in 2 of 3 infected persons. In addition, multiple samples from 1 of these persons and from 2 persons who died were compared to determine the most appropriate specimen type for detection by quantitative reverse transcription PCR (qRT-PCR).

The Study

Of 7 recognized humans infected with Hendra virus, 3 survived. Of these 3 persons, clinical samples were available for 2 survivors. Patient 1 was a 25-year-old woman (veterinarian) in whom a self-limited influenza-like illness (ILI) developed in November 2004 (8). Patient 2 was a 21-year-old woman (veterinary nurse) who showed development of an ILI that progressed to acute encephalitis in July 2008 (9). Although she survived, patient 2 showed persistent, postencephalitic, high-level cognitive deficits. Currently, both patients do not show clinical evidence of relapse.

For this study, specimens were obtained from both patients at various times during acute-phase infection and during the convalescent phase. Blood was tested for IgG and IgM against Hendra virus. Nasopharyngeal aspirate (NPA), blood, urine, and cerebrospinal fluid were tested for viral RNA by using qRT-PCR.


Thumbnail of Serologic and quantitative reverse transcription PCR (qRT-PCR) results for samples from 2 patients infected with Hendra virus, Australia. Testing was performed from the time at which symptoms first developed (black vertical line) until the most recent sample indicated (dashed vertical arrows). IgG (black bars) and IgM (white bars) reactivity was determined by using a modified microsphere immunoassay (10), and a positive control serum sample to determine the cutoff value. Virus RNA w

Figure. . Serologic and quantitative reverse transcription PCR (qRT-PCR) results for samples from 2 patients infected with Hendra virus, Australia. Testing was performed from the time at which symptoms first developed (black...

Both patients showed IgM and IgG responses to Hendra virus. For patient 1, no specimens were collected in the months after the acute phase and by 12 months, no IgM could be detected. However, IgG reactivity has been maintained for 6 years (Figure). Patient 2 has maintained IgM and IgG reactivity for >1.5 years after initial examination. The prolonged IgM response in patient 2 might have been caused by persistent infection or associated with more severe acute encephalitic manifestations. A prolonged IgM response has been observed in persons with West Nile virus meningitis, and encephalitis and may be a general aspect of central nervous system involvement (12,13).

Viral RNA was not detected in any specimen from patient 1 during the acute phase or at the 6-year follow-up (Figure). Multiple samples from patient 2 were positive for virus during a 1-month period during the acute phase (Figure, Table). However, no samples showed positive results for Hendra virus RNA on subsequent follow-up. Thus, neither patient showed evidence of virus shedding after the acute phase (ILI or encephalitis).

To facilitate future PCR testing, we assessed various sample types for their suitability for detection of Hendra virus RNA during the acute phase of infection. In addition to patient 2, samples from 2 other case-patients with Hendra virus infection not described in this report (patients 3 and 4) were tested. Patient 1 was not included because virus shedding was not detected at any time during her infection. Times chosen were from the earliest to the latest time point at which a positive result was obtained by qRT-PCR (Table).

Hendra virus RNA was detected in blood, NPA (or swab specimen), and urine, confirming the suitability of these sample types. Frequency of detection varied for 3 patients. None of the 3 sample types was consistently better than another, and all were suitable choices for diagnostic purposes. Hendra virus RNA was also detected in cerebrospinal fluid, but there were too few samples to determine whether this material was a reliable sample type.


Serologic and PCR results were reported for the 2 patients during the early phase of infection (8,9). Our study followed-up survivors of Hendra virus infection, and found no evidence for prolonged shedding of virus after acute infection. Because of the small total number of human cases and the high case-fatality rate, there are only 3 known surviving patients with Hendra virus infection, 2 whom were included in this study. Therefore, our results provide useful information for clinicians and public health officials for treating individual patients and minimizing the risk for transmission.

However, because of the small number of samples tested in this study, prolonged shedding after acute Hendra virus infection cannot be ruled out. In 1995, a patient who had an episode of aseptic meningitis after caring for 2 Hendra virus–infected horses had a relapse 13 months after the initial episode (5). This patient also showed the potential for virus shedding during management of disease survivors. Thus, further monitoring of current and future survivors and experiments using a suitable animal model is required to answer this question.

The mechanism by which henipaviruses remain dormant is unknown. Virus has not been isolated from persons with relapse cases (2,5). This finding suggests that virus might persist in a noninfectious mutant form analogous to that which occurs with related measles virus during subacute sclerosing panencephalitis (14). In addition, the cellular reservoir for the virus and the mechanism by which it maintains latency are unknown.

It would be desirable to use PCR to test a variety of sample types for diagnosis of infection with Hendra virus. All sample types tested were suitable in terms of sensitivity. However, obtaining an NPA specimen during the acute phase of infection has a potential risk for aerosol contamination, and needle stick injury is a risk if a blood sample is obtained. Collection of a urine sample may be an acceptable risk without reducing the sensitivity of detection and risk to health care staff. This procedure should assist clinicians in management of henipavirus infections.

Ms Taylor is supervising scientist of the Public Health Virology Serology Laboratory of Queensland Health Forensic and Scientific Services. Her main area of expertise is serologic diagnosis of human mosquito-borne viral diseases, such as dengue, and other rare or exotic human viral infections, including Hendra virus.



We thank the 2 patients for making their clinical data available and Brad McCall for providing valuable advice on ethical issues.



  1. Field  HE, Mackenzie  JS, Daszak  P. Henipaviruses: emerging paramyxoviruses associated with fruit bats. Curr Top Microbiol Immunol. 2007;315:13359. DOIPubMedGoogle Scholar
  2. Goh  KJ, Tan  CT, Chew  NK, Tan  PS, Kamarulzaman  A, Sarji  SA, Clinical features of Nipah virus encephalitis among pig farmers in Malaysia. N Engl J Med. 2000;342:122935. DOIPubMedGoogle Scholar
  3. Tan  CT, Goh  KJ, Wong  KT, Sarji  SA, Chua  KB, Chew  NK, Relapsed and late-onset Nipah encephalitis. Ann Neurol. 2002;51:7038. DOIPubMedGoogle Scholar
  4. Chong  HT, Chong  TT. Relapsed and late-onset Nipah encephalitis, a report of three cases. Neurology Journal of Southeast Asia. 2003;8:10912.
  5. O’Sullivan  JD, Allworth  AM, Paterson  DL, Snow  TM, Boots  R, Gleeson  LJ, Fatal encephalitis due to novel paramyxovirus transmitted from horses. Lancet. 1997;349:935. DOIPubMedGoogle Scholar
  6. Wong  KT, Robertson  T, Ong  BB, Chong  JW, Yaiw  KC, Wang  LF, Human Hendra virus infection causes acute and relapsing encephalitis. Neuropathol Appl Neurobiol. 2009;35:296305. DOIPubMedGoogle Scholar
  7. Australian veterinary emergency plan. Version 3.3; 2009 [cited 2012 Jun 28].
  8. Hanna  JN, McBride  WJ, Brookes  DL, Shield  J, Taylor  CT, Smith  IL, Hendra virus infection in a veterinarian. Med J Aust. 2006;185:5624.PubMedGoogle Scholar
  9. Playford  EG, McCall  B, Smith  G, Slinko  V, Allen  G, Smith  I, Human Hendra virus encephalitis associated with equine outbreak, Australia, 2008. Emerg Infect Dis. 2010;16:21923. DOIPubMedGoogle Scholar
  10. Bossart  KN, McEachern  JA, Hickey  AC, Choudhry  V, Dimitrov  DS, Eaton  BT, Neutralization assays for differential henipavirus serology using Biol-Plex protein array systems. J Virol Methods. 2007;142:2940. DOIPubMedGoogle Scholar
  11. Smith  IL, Halpin  K, Warrilow  D, Smith  GA. Development of a fluorogenic RT-PCR assay (TaqMan) for the detection of Hendra virus. J Virol Methods. 2001;98:3340. DOIPubMedGoogle Scholar
  12. Davis  LE, DeBiasi  R, Goade  DE, Haaland  KY, Harrington  JA, Harnar  JB, West Nile virus neuroinvasive disease. Ann Neurol. 2006;60:286300. DOIPubMedGoogle Scholar
  13. Kapoor  H, Signs  K, Somsel  P, Downes  FP, Clark  PA, Massey  JP. Persistence of West Nile virus (WNV) IgM antibodies in cerebrospinal fluid from patients with CNS disease. J Clin Virol. 2004;31:28991. DOIPubMedGoogle Scholar
  14. Garg  RK. Subacute sclerosing panencephalitis. J Neurol. 2008;255:186171. DOIPubMedGoogle Scholar




Cite This Article

DOI: 10.3201/eid1812.120722

Table of Contents – Volume 18, Number 12—December 2012

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.



Please use the form below to submit correspondence to the authors or contact them at the following address:

David Warrilow, Public Health Virology Laboratory, Queensland Health Forensic and Scientific Services, PO Box 594, Archerfield, Queensland 4108, Australia

Send To

10000 character(s) remaining.


Page created: November 21, 2012
Page updated: November 21, 2012
Page reviewed: November 21, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.